● The collaboration brings together more than 100 years of power management history with deep…
Healthcare Private Equity Firm Builds for Growth with Renewed New York Presence NEW YORK–(BUSINESS WIRE)–Kain…
MURRAY, Utah–(BUSINESS WIRE)–FinWise Bank, a subsidiary of FinWise Bancorp, announced today that the Board of…
Dr. Myers brings extensive executive experience leading the development of clinical programs through US and…
Management to host conference call and webcast at 4:30 p.m. ET IRVINE, Calif., March 23,…
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics”…
Publication of annual report for financial year 2022 Annual Shareholders’ Meeting proposed resolutions include re–appointment of…
New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA…
New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA…
New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA…
Prestigious International Awards Program Recognizes Outstanding Financial Technology Products And Companies NEW YORK–(BUSINESS WIRE)–Candidly, the…
Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering…
Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering…
Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering…
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and…
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and…
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and…
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple…
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple…